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Even though, the utility of the hoparln In pts with unstable angina Is 
well esllablt~hed, those results show the controvomtnl role o11 postponing an 
angtoplssty using 11he pre-tmallment with IV hopsrln 11or 48 to 96 hrs, Other 
trials am necessary to evaluate the clinical and economic impact, 
11[ -~, i  0~ The Contr ibut ion  of Adjunct ive S t in t  Uee to 
In-pMient  Cost  With end Without  GPlla/l l lb 
B lockade In the RESTORE Trial 
S, Cull,Jr, S,J, Boccuzzl, J, Roahm, J, Cook, J, Bume1110, W,S, Welntrnub, 
For 11ho The RESTORE Economic Sfucly Omllp: Emery Unlwr~illy, Afl,qnf,'1, 
GA, USA 
RESTORE (Raedomlzed Efficacy o11 Study o11 TIro!flbsn for Oullcomos and Ro- 
s11anoolll) wels a randomized, double.blind, plattobo controlled 1trial ol! 111m111bnn 
In 2,141 pe111enlls undergoing PTCA willhIn 72 houm o11 presents111on with un, 
mblQ engine or ac~11e myocardial Inlam111on (MI), Paflenlla wore 11roalled with 
tlro111bnn 10 ug/kg over 3 mlnullss 11ollowed by a 30 hollr inllut~lon o11 0,15 
ug/klYmln or placebo, At 2 days there w(~ a 38% redgctlon (82% vs 5,4%, p 
0.005) In 11he composllle endpolnf o11 death, non-fatal MI, oomn,~n/aurgely 
dge to PTCA fallgre or recurrent1 lsshemla, ropes11 target vessel PTCA 11or 
recurrent1 isohemta, or silent placement 11or aotuat or thmallened ~bmp11 clo. 
sum of the dilated ndew, A cost ~lb~11ttdy wa~ (~enduoted in 818 patients at 
30 ~lllos, ~,9% o11 p~111enls had ¢,tenls placed as a "bail-out1" 11or ,"agile closure 
~nd 0,1% had slenlls pla(~ed due to sn tnsdoq,'aate msulL No patients I~sd 
planl~ed elective stontlng In RESTORE Hospital cost was $9,95~' wtllhou11 
slants, $14,1180 with 1 or more stants, The additional Cost oll Bloats, account. 
Ing 11or oth~r significant vaflablos was $~,g05 :t 737, The ~dd~fionsl cost o11 
other muttivariat~ corrol~11os ware $19,10311or CADG, $5,448 110r congestive 
failure, $7,t 0B 11or add11110nal PTCA, $8,30511or a myocardial inllar(~tien, $5,334 
11or transfusion requirement and $1,047 for A first PTCA (R Sq 034), Them 
wa~ == fiend to lower costs with ttm111bsn both In the atonted and unstenled 
patients, Patients receiving tlm111ban had a moan hospital coat o11 $9259 :~ 
5,508 wlth0tlt a slont and St 3,862:1 5221 with a Mont. Patients not receiving 
tlro11~ban h~d a moan hospital cost of $10,141 -~ 0,366 without a stoat and 
$14,33g • 6,156 with a steal, Used 11or bailout after acute closure or in the 
setting a11 an tnadedualto result, oven without anlbcosgulatton with coumadin. 
sIenRI will Incrementally add to the hospital cost oll PTCA. 
~ C s n  Tlc lopld lne Be Safely D iscont inued TWo 
Weeks After  Coronary Stent P lacement?  
P,B, Bep.3or, D,E, Grill, S,J. Molby, M,R, Bell, D,R. Holmes, Jr,, Mayo Chnic, 
Rochester, Minne.~ota, USA 
To determine the frequency ot stoat thrombosis (ST) and other adverse 
ovonls 15 to 30 days after coronar~ steal placement when ticlopidine is 
stopped after 14 days, we analyzed 489 pts who undonNent successful stent 
placomen11 between 5t96 and 3/97. Pts on chronic wadarin, in shock, and 
in protocols mqumng 4 weeks el tic-lopldtno were excluded; ttclopidino was 
stopped after 2 weeks in all other pts (n = 489), Mean ago was 64 ym; 47% 
had suffered MI, 20% had undergone CABG, 63% had multivessel disease, 
Indications for the stonts were dtssectlontabn~pt closure (33%), suboptimal 
balloon angloplasty (16%), and elective (51%,), The 489 pts received J & J 
comnanJ (76%), GR (21%). and J & J biliary stents (3%); 1.5 steals per pt 
worn placed, Moan nominal slant size was 33 :~ 0,6 ms. High-pressure 
Inflations (_~12 aim) were performed in all pts (moan 17 ± 4 aim). Moan 
m.~tdunl stenosls woe 4 -~ 8% (visual estimate) Pts at increased ask of stoat 
thrombosis (14%) were also treated with Enoxapartn 30-60 mg SQ for 10-14 
dnys. 
Resutts: Adverse events ~ t4 days after stent placement OCCUlTed in 9 
pts (1B%); 5 pts died and ST occurred in 4 others. However, there were 
no deaths, Mrs, CABG or PTCA ptecedures, and ST did not occur, on the 
15th-30th days. Neutrepenia did net occur in any pt. 
Conclusions: Stepping ticlopldine 14 days after stent placement is asso- 
ciated with a veal low 11mquoncy o11 ST (0% in this study), less than the 1% 
frequency ot life-threatening ticlopidlne-induced neutmpenia. 
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Dur ing PTCA by Intravenous Pre-treatment'()t  
ATP-sensit ive K+ Channel Opener  NICORANDIL 
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S. W",tansbe Gifu Prefectural Hospital, Cifu, Japan 
Background: To establish whether pretreatment of nicorandil (NC), ATP-sen- 
strive K+ channel opener, induce preconditioning effect independent of the 
increase cf collateral recruitment (F) in patients. 
Methods: 28 pts with angina who underwent PTCA to proximal LAD 
stenosis were randomly allocated to pretreatment of NC (4 mg IV 5 sin 
before initial ballooning) (n = 13) or conventional treatment (N = 14). Pts 
who experienced angina within 7 days before PTCA were excluded, ~mTc 
tetmllosmln were Injected dudng balloon initiation, and quantitative analysis 
o11 tschemic severity during Inflation was calculated (SS), ECG was recorded 
during 2 mln inflation to calculate the sum o11 ST elevation (~ST). 
Results: Close cormlatlon was observed between SS and ~ ST in both 
group (R2:contml 0,77, NC 0,81 ) as shown in figure, NC resulted in slgnlllicsnt 
suppression o11 ST elevation (SS adjusted ~: S'E, Control 1,88 mV va NC 1,09 
mV p < 0,01 ), The line of regression In control Is significantly s11eopor than NO, 
suggesting coil pro11ectlve affect against ischemla by NC which is iedopen~nt 
o11 flow vadn111on, 
• / L -J 
Cenetttsion: NC prellreatment result in tho mducti .m el myocardial pmcon, 
dittoning indopond0nl of flew vanatien 
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Dysfunction During Percutaneous Coronary 
Anglop lasty  
M,F. Stoddard, A,MA. Hasnie, M. Leesar, R. Both Un~vets@ et Lou~st~lte, 
Loulsvflle, KY, USA 
Adenosine pmtroatment increases the resistance el human myocardlum to 
ischomia as assessed by ST-segment shifts, in a manner similar to iscbem~c 
preconditioning. It is unknown if either adenosine pretreatment or ischem=c 
preconditioning protects the human heart agam.~t he adverse effects el 
ischemta on systolic or diastolic function Thus, 18 pie hewn 0 PTCA were 
randomized to receive a tO-min intraCorenan/infusion el saline (controls |C|. 
n = 9) or adenosine-::' mgtmin (ADO, n = 9). Ten sin after mfusion, pts had 
three 2-sin inflations, each separated by 5 s in  LV mllow propagation rate 
(LVPR) was measured at the end of each inffation by color Mmode echo 
Wall motion was assessed by the conterline method 14- and 2-chamber). 
Result: In C, LVPR decreased dunng each inflation, but progressively 
less from inflation 1 to 3, In contrast, in ADO the decreases m LVPR dunng 
inflation 1, 2 and 3 were similar. LVPR dunng inflation t was less in C vs 
ADO (p - 005) (table) 
LVPR tCtlrt,$) ChoIdal 5hollenm~ {mm) 
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In C, chordal shortening (CS) in the ischemic zone decreased dunng each 
inflation, but less so dunng inflations 2. and 3 comr)amd to inflation I (both p 
= 0.0005). In &.DO, the decreases in CS were sim=lar for inflations 1, 2 and 3. 
CS durmg inflation I was greater in ADO vs C (p 0.02). CS dunng inflation 
3 in C was comparable to inflation 1 in ADO. 
Conclusions: To our knowledge, this is the first study showing that adeno- 
sine preconditions human myocardium against ischemia-induced systolic 
and diastolic dyslunction. This is also the lirst evidence that ischemic pre- 
conditioning attenuates mechanical dyslunction dunng acute myocardial is- 
chemia in man. 
